Pandemrix is an influenza vaccine for influenza pandemics, such as the H1N1 2009 flu pandemic colloquially called the swine flu. The vaccine was developed by GlaxoSmithKline and patented in September 2006.
The vaccine is one of the H1N1 vaccines approved for use by the European Commission in September 2009 upon the recommendations of the European Medicines Agency (EMEA). The vaccine is only approved for use when an H1N1 influenza pandemic has been officially declared by the World Health Organization (WHO) or European Union (EU). This vaccine was initially developed as a pandemic mock-up vaccine using an H5N1 strain.
Side effects
* Very common (affects more than 1 in 10 people):
o Headache
o Tiredness
o Pain, redness, swelling or a hard lump at the injection site
o Fever
o Aching muscles, joint pain
* Common (affects at least 1 in 100):
o Warmth, itching or bruising at the injection site
o Increased sweating, shivering, flu-like symptoms
o Swollen glands in the neck, armpit or groin
* Uncommon (affects at least 1 in 1,000):
o Tingling or numbness of the hands or feet
o General constitutional upset of sleepiness or sleeplessness, generally feeling unwell, dizziness.
o Diarrhoea, vomiting, stomach pain, feeling sick
o Skin reactions of itching, rash or urticaria (hives)
* Rare (affects at least 1 in 10,000):
o Serious generalised allergic reactions of anaphylaxis
o Fits
o Severe stabbing or throbbing pain along one or more nerves
o Low blood platelet count which can result in bleeding or bruising
* Very Rare (affects less than 1 in 10,000 people):
o Vasculitis
o Neurological disorders such as encephalomyelitis, neuritis or Guillain–Barré syndrome temporary paralysis
Recent Comments Gravatars